Human papillomavirus (HPV)-positive cervical cancer develops under persistent metabolic, replicative, and oxidative stress and frequently exhibits limited sensitivity or acquired resistance to cisplatin-based concurrent chemoradiotherapy (CCRT). In this context, ferroptosis represents a potential therapeutic vulnerability, yet the regulatory networks that sustain ferroptosis resistance in HPV-pos…
